Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing scale-up fermentation processes.

Michel Thiry1, Doriano Cingolani

  • 1Eurogentec S.A., Parc scientifique du Sart Tilman, B-4102 Seraing, Belgium. m.thiry@eurogenetics.com

Trends in Biotechnology
|February 14, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis.

PLoS neglected tropical diseases·2012
Same author

Production, quality control, stability and pharmacotoxicity of cGMP-produced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris.

Vaccine·2008
See all related articles

Optimizing fermentation processes for biopharmaceuticals involves tailoring standard protocols for Escherichia coli, Saccharomyces cerevisiae, and Pichia pastoris. This ensures efficient scale-up while adhering to good manufacturing practices and equipment constraints.

Area of Science:

  • Biotechnology and bioprocess engineering
  • Microbial fermentation for biopharmaceutical production

Background:

  • Fermentation process optimization is crucial for increasing product yield.
  • Compliance with good manufacturing practices (GMP), equipment limitations, and operational scale are key considerations.
  • Genetically modified microorganisms like Escherichia coli, Saccharomyces cerevisiae, and Pichia pastoris are commonly used for recombinant protein overproduction.

Purpose of the Study:

  • To outline a general philosophy for efficient scale-up of fermentation processes.
  • To provide a framework for developing tailored fermentation processes for biopharmaceutical production.
  • To address the multidisciplinary nature of biopharmaceutical manufacturing.

Main Methods:

  • Leveraging standard textbook processes for common microbial hosts (E. coli, S. cerevisiae, P. pastoris).

Related Experiment Videos

  • Developing customized fermentation strategies based on specific product and scale requirements.
  • Integrating principles of good manufacturing practices throughout the process development lifecycle.

    • Main Results:

    • A systematic approach to scaling up fermentation processes has been devised.
    • The methodology facilitates the efficient production of biopharmaceuticals using established microbial platforms.
    • Consideration of GMP and equipment constraints is integrated into the scale-up strategy.

    Conclusions:

    • An efficient, multidisciplinary philosophy for scaling up fermentation processes is presented.
    • Tailored processes based on standard microbial systems enable effective biopharmaceutical production.
    • Successful scale-up requires careful consideration of regulatory compliance and technical feasibility.